Michael Ullmann - Johnson Johnson Executive Vice President, General Counsel
| JNJ Stock | EUR 146.92 0.38 0.26% |
President
Mr. Michael H. Ullmann is Executive Vice President, General Counsel of the Company. Mr. Ullmann joined the Company in 1989 as a corporate attorney in the Law Department. He was appointed Corporationrationrate Secretary in 1999 and served in that role until 2006. During that time, he also held various management positions in the Law Department. In 2006, he was named General Counsel, Medical Devices and Diagnostics and was appointed Vice President, General Counsel and became a member of the Executive Committee in 2012. In April 2016, Mr. Ullmann was named Executive Vice President, General Counsel since 2016.
| Age | 60 |
| Tenure | 8 years |
Similar Executives
| Found 10 records | PRESIDENT Age | ||
| Ann Tripp | The Hanover Insurance | 60 | |
| Warren Barnes | The Hanover Insurance | 57 | |
| John Roche | The Hanover Insurance | 59 | |
| Richard Lavey | The Hanover Insurance | 55 | |
| Mark Welzenbach | The Hanover Insurance | 59 | |
| Mark Wilcox | Selective Insurance Group | 55 | |
| Mark Berthiaume | The Hanover Insurance | 62 | |
| Bryan Salvatore | The Hanover Insurance | 58 | |
| Jeffrey Farber | The Hanover Insurance | 58 | |
| Michael Lanza | Selective Insurance Group | 61 | |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| A Washington, Independent Director | ||
| Jennifer Doudna, Independent Director | ||
| Alex Gorsky, Chairman of the Board, Chief Executive Officer | ||
| Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
| Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
| Marillyn Hewson, Independent Director | ||
| Ronald Williams, Independent Director | ||
| Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| Michael Ullmann, Executive Vice President, General Counsel | ||
| Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
| D Davis, Independent Director | ||
| Hubert Joly, Independent Director | ||
| Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
| Anne Mulcahy, Lead Independent Director | ||
| Mary Beckerle, Independent Director | ||
| Joseph Wolk, Chief Financial Officer, Executive Vice President | ||
| Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer | ||
| Ian Davis, Independent Director | ||
| Paulus Stoffels, Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group | ||
| Mark McClellan, Independent Director | ||
| Charles Prince, Independent Director | ||
| Peter Fasolo, Chief Human Resource Officer, Executive Vice President | ||
| Mark Weinberger, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 443.95 B | |||
| Price To Book | 6.23 X | |||
| Price To Sales | 4.94 X | |||
| Revenue | 94.94 B | |||
| EBITDA | 28.97 B | |||
| Net Income | 17.94 B | |||
| Total Debt | 26.89 B | |||
| Cash Flow From Operations | 21.19 B | |||
| Price To Earnings To Growth | 3.83 X | |||
| Number Of Employees | 33 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Johnson Stock
When determining whether Johnson Johnson is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Johnson Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Johnson Johnson Stock. Highlighted below are key reports to facilitate an investment decision about Johnson Johnson Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Johnson Stock refer to our How to Trade Johnson Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.